• Home
  • Research
  • Plant-Based Peptide with Phytonutrients Status Post Bone Marrow Transplant

Plant-Based Peptide Enteral Nutrition with Phytonutrients in a Pediatric Patient Status Post Bone Marrow Transplant: A Case Report

Authors: Melissa Bailey, MS, RD, CNSC, LDN; Kelsey Bullard, MS, RD; Vanessa Millovich, DCN, RDN, LDN

Abstract accepted by the American Society for Parenteral and Enteral Nutrition (ASPEN) and published in the March 2020 digital supplement of the Journal of Parenteral and Enteral Nutrition (JPEN)1.

The purpose of this study was to document the successful concomitant use of a plant-based, phytonutrient-containing enteral formula and immunosuppressive medications. A 3-year-old male with a history of Hemophagocytic Lymphohistiocytosis (HLH) and status post Bone Marrow Transplant (BMT) was transitioned to a plant-based pediatric peptide enteral formula. Weight and tolerance were monitored.

A pediatric bone marrow transplant patient who switched2 to Kate Farms had:

  • Resolved symptoms of GI intolerance3

  • Weight gain

  • No reported medication interactions4


1. Bailey, M., et al. Plant-based peptide enteral nutrition with phytonutrients in a pediatric patient status post bone marrow transplant: A case report. J Parenter Enteral Nutr. 2020; 44(3):226-227.

2. Previous formulas included standard dairy-based infant formula, hypoallergenic infant and junior formulas, partially hydrolyzed dairy-based pediatric formula with soluble fiber.

3. Resolved symptoms of GI intolerance included nausea, vomiting, large/loose stools, bloody stools.

4. No documentation of the phytonutrient blend interfering with any of the anti-rejection medications was noted.